Per Kogner

12.2k total citations
232 papers, 7.7k citations indexed

About

Per Kogner is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Per Kogner has authored 232 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 172 papers in Neurology, 113 papers in Molecular Biology and 68 papers in Cancer Research. Recurrent topics in Per Kogner's work include Neuroblastoma Research and Treatments (172 papers), Cancer, Hypoxia, and Metabolism (61 papers) and Neuroendocrine Tumor Research Advances (40 papers). Per Kogner is often cited by papers focused on Neuroblastoma Research and Treatments (172 papers), Cancer, Hypoxia, and Metabolism (61 papers) and Neuroendocrine Tumor Research Advances (40 papers). Per Kogner collaborates with scholars based in Sweden, United States and Norway. Per Kogner's co-authors include John Inge Johnsen, Tommy Martinsson, Baldur Sveinbjørnsson, Helena Carén, Frida Ponthan, Frida Abel, Lova Segerström, Ninib Baryawno, Jacob Odeberg and Guðmundur H. Guðmundsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Per Kogner

225 papers receiving 7.6k citations

Peers

Countries citing papers authored by Per Kogner

Since Specialization

Citations

This map shows the geographic impact of Per Kogner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Kogner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Kogner more than expected).

Fields of papers citing papers by Per Kogner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Kogner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Kogner. The network helps show where Per Kogner may publish in the future.

Co-authorship network of co-authors of Per Kogner

This figure shows the co-authorship network connecting the top 25 collaborators of Per Kogner. A scholar is included among the top collaborators of Per Kogner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per Kogner. Per Kogner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Heterogeneous SSTR2 target expression and a novel KIAA1549::BRAF fusion clone in a progressive metastatic lesion following 177Lutetium-DOTATATE molecular radiotherapy in neuroblastoma: a case report 2024 ·Frontiers in Oncology ·(unknown), Susanne Fransson, (unknown), (unknown), Per Grybäck, (unknown), (unknown), Anna Djos, Henrik Fagman, Helene Sjögren, (unknown), Nikolas Herold, Per Kogner, Donald Granberg, Mark N. Gaze, Tommy Martinsson, Kasper Karlsson, Jakob Stenman	0
2	Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), James I. Geller, Martine van Grotel, Marc Ansari, Éric Bouffet, Archie Bleyer, (unknown), Michael Sullivan, Alwin D. R. Huitema, (unknown), Per Kogner, Rudolf Maibach, Allison F. O’Neill, Vassilios Papadakis, Kaukab Rajput, Gareth J. Veal, Penelope Brock, (unknown), Marry M. van den Heuvel‐Eibrink	0
3	The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma 2024 ·Cancer Letters ·(unknown), (unknown), (unknown), Diana Treis, (unknown), (unknown), (unknown), Emma Åkerlund, Brinton Seashore‐Ludlow, (unknown), Per Kogner, John Inge Johnsen, Malin Wickström	2
4	Occurrence of cancer in Marfan syndrome: Report of two patients with neuroblastoma and review of the literature 2024 ·American Journal of Medical Genetics Part A ·(unknown), A M Delgado-Vega, Fulya Taylan, Kristina Lagerstedt‐Robinson, (unknown), Niklas Pal, Henrik Fagman, Florian Puls, (unknown), Jakob Stenman, (unknown), Susanne Fransson, Teresita Díaz de Ståhl, Torben Ek, Ruth H. Palmer, Bianca Tesi, Per Kogner, Tommy Martinsson, Ann Nordgren	0
5	Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature 2024 ·JCI Insight ·Shenglin Mei, (unknown), (unknown), (unknown), Bronte Manouk Verhoeven, Ting Zhao, Xiangyun Li, (unknown), (unknown), Hirak Sarkar, Thale Kristin Olsen, Malin Wickström, Jakob Stenman, (unknown), Peter V. Kharchenko, Philip J. Saylor, John Inge Johnsen, David B. Sykes, Per Kogner, Ninib Baryawno	8
6	Loss of Chromosome Y in Neuroblastoma Is Associated With High‐Risk Disease, 11q‐Deletion, and Telomere Maintenance 2024 ·Genes Chromosomes and Cancer ·Anna Djos, Johanna Svensson, (unknown), Ganesh Umapathy, Staffan Nilsson, Torben Ek, Hartmut Vogt, (unknown), Ingrid Øra, Catarina Träger, Per Kogner, Tommy Martinsson, Susanne Fransson	2
7	METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma 2023 ·Nucleic Acids Research ·Roshan Vaid, (unknown), (unknown), Rebeca Burgos‐Panadero, Anna Djos, (unknown), Kristina Lundberg, Christoph Bartenhagen, (unknown), (unknown), Carina Sihlbom, Susanne Fransson, John Inge Johnsen, Per Kogner, Tommy Martinsson, Matthias Fischer, Tanmoy Mondal	27
8	Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the TERT and ATRX Genes 2023 ·Cancers ·Anna Djos, (unknown), Roshan Vaid, (unknown), Ganesh Umapathy, Susanne E. Reinsbach, (unknown), Jakob Stenman, Helena Carén, Torben Ek, Tanmoy Mondal, Per Kogner, Tommy Martinsson, Susanne Fransson	3
9	DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma 2022 ·JCI Insight ·Thale Kristin Olsen, Cecilia Dyberg, (unknown), (unknown), Jelena Milosevic, Jane Ding, Jörg Otte, (unknown), Ida Hed Myrberg, Ellen M. Westerhout, Jan Köster, Rogier Versteeg, Han‐Fei Ding, Per Kogner, John Inge Johnsen, David B. Sykes, Ninib Baryawno	21
10	PPM1D Is a Therapeutic Target in Childhood Neural Tumors 2021 ·Cancers ·Jelena Milosevic, Diana Treis, Susanne Fransson, Gabriel Gallo-Oller, Baldur Sveinbjørnsson, Nina Eißler, Keiji Tanino, Kazuyasu Sakaguchi, Tommy Martinsson, Malin Wickström, Per Kogner, John Inge Johnsen	7
11	Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53 2020 ·Hereditary Cancer in Clinical Practice ·(unknown), Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham, Svetlana Bajalica‐Lagercrantz	6
12	Inhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth 2019 ·Cancers ·Cecilia Dyberg, (unknown), Thale Kristin Olsen, Bertha Brodin, Marcel Kool, Per Kogner, John Inge Johnsen, Malin Wickström	10
13	SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells In Vitro 2019 ·Cancers ·(unknown), (unknown), Malin Wickström, Peter J. Coopman, (unknown), Per Kogner, John Inge Johnsen, Ugo Moens, Baldur Sveinbjørnsson	7
14	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma 2016 ·Clinical Cancer Research ·Yumeng Mao, Nina Eißler, Katarina Le Blanc, John Inge Johnsen, Per Kogner, Rolf Kiessling	107
15	RNA Helicase A Is a Downstream Mediator of KIF1Bβ Tumor-Suppressor Function in Neuroblastoma 2014 ·Cancer Discovery ·Zhi Xiong Chen, Karin Wallis, (unknown), (unknown), (unknown), Daniel Ramsköld, Ulf Hellman, Rickard Sandberg, Rajappa S. Kenchappa, (unknown), John Inge Johnsen, Per Kogner, Susanne Schlisio	43
16	Early high-dose treatment: SCT results from the European High Risk Neuroblastoma Study 2011 ·IRIS ·Ruth Ladenstein, Ulrike Pöetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Mališ, Walentyna Balwierz, Ellen Ruud, Per Kogner, (unknown), (unknown), Maja Beck‐Popovic, (unknown), Miklós Garami, Toby N. Trahair, D Valteau-Couanet	1
17	Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy 2010 ·Cancer Research ·Tommy Martinsson, Therése Eriksson, Jonas Abrahamsson, Helena Carén, Magnus Hansson, Per Kogner, Sattu Kamaraj, Christina Schönherr, (unknown), Kristina Ruuth, Ruth H. Palmer, Bengt Hallberg	59
18	Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinase/Akt Signaling Inhibit Wnt/β-Catenin Pathway Cross-Talk and Suppress Medulloblastoma Growth 2009 ·Cancer Research ·Ninib Baryawno, Baldur Sveinbjørnsson, Staffan Eksborg, Ching‐Shih Chen, Per Kogner, John Inge Johnsen	118
19	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours 2008 ·Biochemical Journal ·Helena Carén, Frida Abel, Per Kogner, Tommy Martinsson	202
20	The use of fine-needle aspiration cytology in the molecular characterization of neuroblastoma in children 1999 ·Cancer ·(unknown), Tommy Martinsson, Edneia Tani, Sture Falkmer, Catarina Darnfors, Lambert Skoog, Per Kogner	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact